IMRX Immuneering
- 1.630
- -0.090-5.23%
- 1.640
- +0.010+0.60%
Immuneering News
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)
Immuneering Analyst Ratings
Immuneering Analyst Ratings
Buy Rating Affirmed for Immuneering on Solid Trial Progress and Insider Confidence
Analysts Are Bullish on These Healthcare Stocks: Immuneering (IMRX), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Jefferies Downgrades Immuneering to Hold From Buy, Cuts Price Target to $3 From $16
Chardan Lowers Price Target on Immuneering to $16 From $21, Keeps Buy Rating
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Afya (AFYA) and Urogen Pharma (URGN)
Analysts Are Bullish on These Healthcare Stocks: 2seventy Bio (TSVT), Immuneering (IMRX)
Immuneering: Hold Rating Amidst Potential and Uncertainties in Drug Efficacy
Immuneering Analyst Ratings
Immuneering Analyst Ratings
Immuneering's IMM-1-104 Progress Garners Buy Rating Amid Favorable Phase 2 Dose Determination and Anticipated Phase 1 Data
Immuneering Analyst Ratings
Oppenheimer Reiterates Outperform on Immuneering, Maintains $25 Price Target
Analyst Maintains Buy Rating on Immuneering Amidst Promising Clinical Progress and Extended Cash Runway
Immuneering Analyst Ratings
Analysts Conflicted on These Healthcare Names: Immuneering (IMRX), Medtronic (MDT) and Gilead Sciences (GILD)
Promising Clinical and Regulatory Milestones for Immuneering's Lead MAPK Inhibitor Program Propel Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Immuneering (IMRX), Halozyme (HALO) and Repligen (RGEN)
Analysis
Price Target
No Data
